The Legal 500 Publishes “United States: Pharmaceutical Advertising” Q&A by Lustigman and Spina

Olshan’s Advertising, Marketing & Promotions Practice Group chair Andrew Lustigman and associate Morgan Spina have authored the chapter “United States: Pharmaceutical Advertising” in The Legal 500: Pharmaceutical Advertising Country Comparative Guide, a country-specific Q&A providing an overview of pharmaceutical advertising laws and regulations applicable in the United States. Topics covered in the Q&A include how the advertising of medicines are regulated in the US, self-regulatory codes of practice applying to the advertising of medicines, how to define advertising for regulatory purposes, whether companies are required to have material approval prior to releasing a new drug, and more.

You can read the entire Q&A here.

Add a comment

Type the following characters: november, niner, foxtrot, papa, three

* Indicates a required field.


Recent Posts



Jump to Page

Necessary Cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytical Cookies

Analytical cookies help us improve our website by collecting and reporting information on its usage. We access and process information from these cookies at an aggregate level.